Novo Bets $1.3B On Nanexa Drug Tech Amid Obesity Push
Novo Nordisk has agreed to pay up to about €1.165 billion ($1.3 billion) under an exclusive license and collaboration agreement for Swedish drug-delivery company Nanexa's PharmaShell technology....To view the full article, register now.
Already a subscriber? Click here to view full article